Harry E. Gruber, M.D., one of the pioneers in gene therapy, co-founded Tocagen and led the company as chief executive officer before assuming the role of president, research and development in November 2016. He has been a member of the board of directors since August 2007. Dr. Gruber served as our chief executive officer from August 2007 to November 2016 and served as chairman of our board of directors from August 2007 to October 2014. Dr. Gruber is a co-founder of Tocagen and has been the co-founder and/or co-inventor of key technology for the following publicly held companies: Viagene Inc., a gene therapy company acquired by Novartis Pharmaceuticals; Gensia Inc., a biopharmaceutical company acquired by Teva Pharmaceuticals Industries, Ltd.; INTERVU Inc., a technology company acquired by Akamai Technologies, Inc.; Kintera, Inc., a technology company acquired by Blackbaud; and Aramed, Inc., a biopharmaceutical company. He is the author of more than 100 original scientific articles and an inventor on more than 100 issued and pending patents. Dr. Gruber holds a medical degree and bachelor’s degree from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego, where he subsequently joined the medical school faculty until founding Gensia Inc.